Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
Abeona Therapeutics (Nasdaq: ABEO) will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update. Results will be released in a press release before the call, with live access via phone and webcast, plus a 30-day archived replay on the company’s investor website.
Details
News Market Reaction – ABEO
On Aug 6, the day this news came out, ABEO closed 1.47% above the previous close. Argus tracked a peak move of +14.4% during that session. Our momentum scanner recorded 3 alerts for this stock that day.
Data tracked by StockTitan Argus for the Aug 6 session.
Key Figures
- Results period
- Q2 2026
- Financial results to be discussed on the conference call
- Conference call date
- August 13, 2026
- Scheduled financial results conference call
- Conference call time
- 8:30 a.m. ET
- Scheduled call start time
- Replay availability
- 30 days
- Archived webcast availability following the call
Previous Conferences,earnings date Reports
-
Scheduled third-quarter 2025 results call and investor conference participation
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its financial results for the second quarter of 2026 and provide a corporate update. Abeona will announce its financial results for this period in a press release to be issued prior to the call.
To access the live conference call, please dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and enter Entry Code: 245916 approximately five minutes prior to the start of the call.
A live, listen-only webcast and archived replay of the call can be accessed within the Investors & Media section of Abeona’s website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available for 30 days following the conclusion of the call.
About Abeona Therapeutics®
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Contacts: Investor and Media: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor: Lee M. Stern Meru Advisors lstern@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.